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Atrial Fibrillation and Diffuse
Left Ventricular Fibrosis,
a Causal Association?*
Henry R. Halperin, MD,†
Saman Nazarian, MD, PHD‡
Baltimore, Maryland
Late gadolinium enhanced magnetic resonance imaging
(MRI) is an established technique for quantification of
dense myocardial fibrosis (1). Cohesive regions of myocar-
dial fibrosis, such as infarcted myocardium, are character-
ized by expanded extracellular matrix due to replacement of
normal myocytes with collagen. Gadolinium contrast agents
perfuse into and wash out of normal myocardium relatively
rapidly. However, because of increased extracellular matrix
and decreased capillary density, gadolinium contrast is
retained within fibrotic myocardium (2). Late gadolinium
enhanced MRIs are obtained by using an inversion recovery
pulse that suppresses the signal from normal myocardium
and results in hyperenhancement of signal from the gado-
linium retained in dense myocardial fibrosis (3). If the
See page 2402
myocardial fibrosis is diffuse rather than focal, however,
gadolinium contrast may be evenly retained throughout the
diffusely fibrotic myocardium. Thus, normal myocardium
for appropriate selection of the inversion time may be
absent. Additionally, the signal intensity variation of dif-
fusely fibrotic areas compared with that of normal tissue
may be minimal. As a result, diffuse myocardial fibrosis may
be overlooked despite substantial retention of gadolinium.
In contrast, the T1 mapping technique detects diffuse
myocardial fibrosis by providing a quantitative measure of
the myocardial T1 relaxation times. Diffuse myocardial
fibrosis shortens the T1 relaxation time because of retention
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studies have used T1 mapping to quantify diffuse fibrosis in
patients with heart failure, aortic regurgitation, adult con-
genital heart disease, nonischemic cardiomyopathy, and
myotonic muscular dystrophy (4–8). It is important to note
that histopathologic processes other than diffuse myocardial
fibrosis, such as fatty infiltration, edema, amyloid protein
deposition, and iron deposition, also influence the myocar-
dial T1 relaxation time. Additionally, the post-contrast
myocardial T1 time may vary as a function of parameters
such as contrast dose, delay time of MRI scan after contrast
injection, patient hematocrit, and glomerular filtration rate.
In this issue of the Journal, Ling et al. (9) examined the
association of diffuse myocardial fibrosis of the left ventricle
with atrial fibrillation. The authors performed myocardial
T1 mapping in 67 patients with atrial fibrillation (60%
paroxysmal, 40% persistent) and 23 healthy volunteers.
Patients with persistent atrial fibrillation had larger left
atrial volume and lower left ventricular ejection fraction
when compared with patients with paroxysmal atrial fibril-
lation and healthy volunteers. The post-contrast left ven-
tricular T1 relaxation time was significantly different across
groups: shortest in patients with persistent atrial fibrillation,
modestly short in patients with paroxysmal atrial fibrillation,
and longest in healthy volunteers. The subgroup of patients
with lone atrial fibrillation also had shorter left ventricular
T1 relaxation times when compared with age- and sex-
matched controls. In multivariable analysis, age, atrial fibril-
lation category, and left ventricular ejection fraction were
independently associated with the post-contrast left ventric-
ular T1 relaxation time.
Ling et al. (9) provided strong evidence for an association
between atrial fibrillation and the presence of diffuse left
ventricular myocardial fibrosis. They asserted 2 possible
explanations for the association they uncovered: 1) diffuse
interstitial fibrosis may occur as a result of atrial fibrillation
and tachycardia-mediated cardiomyopathy; or 2) diffuse
interstitial fibrosis may reflect the presence of an underlying
cardiomyopathy that precedes and contributes to the devel-
opment of atrial fibrillation. Certainly, the association may
also be due to a combination of the above explanations.
Alternatively, unmeasured confounding due to a third factor
that is independently associated with atrial fibrillation and
diffuse fibrosis may have led to the association. Given the
implications of the investigators’ findings upon strategies for
the follow-up and treatment of patients with atrial fibrilla-
tion, it is important to consider the weight of evidence for
any causal effect of atrial fibrillation upon diffuse ventricular
fibrosis. The English epidemiologist, Sir Austin Bradford
Hill, proposed several criteria required as minimum evi-
dence for the presence of a causal association between 2
variables (10). The first of these criteria concerns the
strength of association. Although it is difficult to compare the
magnitude of association across variables, the magnitude of
association between the presence of any atrial fibrillation
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AF, Diffuse Ventricular Fibrosis, and Causality December 11, 2012:2409–10and the myocardial T1 relaxation time (75.2 ms) in the
multivariable model appears remarkably strong. Another
criterion is the specificity of association. Atrial fibrillation is
associated with a myriad of other comorbidities, and it is
difficult to dissect the effect of each comorbid condition
upon diffuse ventricular fibrosis. However, shorter T1 re-
laxation times in patients with lone atrial fibrillation than in
healthy volunteers appears to support the specificity of this
association. The biological gradient, or dose-response rela-
tionship criterion, has been nicely demonstrated in the
stronger magnitude of association between the T1 relax-
ation time and persistent versus paroxysmal categories of
atrial fibrillation. The biological plausibility criterion was
ighlighted by Hill (10) as a criterion we cannot demand
ecause “what is biologically plausible depends upon the
iological knowledge of the day.” Nevertheless, it is cer-
ainly biologically plausible that atrial fibrillation may lead
o diffuse ventricular fibrosis through multiple mechanisms,
ncluding tachycardia-mediated cardiomyopathy, reduced
trial contribution to cardiac output and thus increased work
f ventricles, chronic microemboli, chronic atrioventricular
yssynchrony, and chronic interventricular dyssynchrony
ue to aberrant conduction. Another important criterion is
oherence, or the compatibility of the cause and effect
nterpretation of data with the generally known facts of the
atural history and biology of the disease. That atrial
brillation may have an etiologic role in formation of diffuse
entricular fibrosis is not incompatible with our current
nowledge of the morbidity and mortality that is associated
ith atrial fibrillation.
Some of the Hill criteria for causality remain untested
ith regard to the association of atrial fibrillation with
iffuse ventricular fibrosis. Because this is the first report of
n association between atrial fibrillation and diffuse myo-
ardial fibrosis, Hill’s criterion of consistency of association has
ot yet been assessed. Another important criterion that
annot be assessed by the presented cross-sectional study is
he temporality of association, which will require examination
f ongoing population-based cohorts with MRI T1 map-
ing as well as atrial fibrillation incidence data. Future
tudies of left ventricular T1 relaxation in patients with
trial fibrillation randomized to rhythm versus rate control
ay satisfy the experiment criterion. Finally, studies of the
ssociation of other atrial and ventricular arrhythmias with
iffuse ventricular fibrosis will be necessary to strengthen the
rgument for causality from an analogy standpoint. TThe possibility that atrial fibrillation may have a causal role
n the development of diffuse ventricular myocardial fibrosis is
ne that cannot be ignored. Such a causal role would signifi-
antly change our understanding of this arrhythmia and pro-
ide stronger rationale for the development of antiarrhythmic
gents as well as ablation methodologies for improved rhythm
ontrol. Future studies that focus on uncovering the direction
f association between atrial fibrillation and diffuse myocardial
brosis are warranted.
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